On January 18, 2017 the SEC instituted a settled proceeding against Orthofix International. According to the SEC: "From at least 2011 to 2013, senior personnel at Orthofix Brazil employed at least four schemes, with third-party commercial representatives and distributors, to make improper payments to doctors employed at government-owned hospitals to induce them to use Orthofix's products, thereby increasing sales. The improper payments to doctors employed at government hospitals were improperly recorded as legitimate expenses and generated illicit profits to Orthofix of approximately $2,928,000. Orthofix also failed to devise and maintain a system of internal accounting controls sufficient to provide reasonable assurances to detect and prevent such payments by Orthofix Brazil, despite the fact that Orthofix had been charged by the Commission in 2012 with violating the books and records and internal controls provisions of the FCPA in connection with bribes paid to Mexican officials by its Mexican subsidiary."

On January 18, 2017 the SEC announced in a press release that Orthofix International has agreed to admit wrongdoing and pay a penalty to settle charges. According to the SEC: Orthofix "improperly booked revenue in certain instances and made improper payments to doctors at government-owned hospitals in Brazil in order to increase sales."